Oritinib mesylate (SH-1028 mesylate) is used as a selective, orally active, pyrimidine-based irreversible EGFR inhibitor for the treatment of tumors harboring EGFR-sensitive and EGFR T790M resistance mutations; it significantly inhibits the proliferation of tumor cells with these EGFR mutations.